Verastem, Inc. (VSTM)
| Previous close | 10.84 |
| Open | 10.89 |
| Bid | 10.14 x 100 |
| Ask | 10.27 x 400 |
| Day's range | 10.19 - 11.02 |
| 52-week range | 4.32 - 15.12 |
| Volume | |
| Avg. volume | 147,282 |
| Market cap | 258.898M |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.96 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 28.79 |
Business WireVerastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
BOSTON, April 18, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience, to chief medical officer where he will lead the Company’s clinical and medical strategy. Dr. Hayslip succeeds Louis J. Denis, M.D., who recently departed the company.
Business WireVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 04, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 35,000 shares of its common stock to four new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees’ acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have
Business WireGlobal Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
BOSTON, March 18, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced new results from the first-ever global LGSOC Patient Impact Survey, developed with patient advocates and community medical leaders to better understand and address the complex needs and experiences of those living with low-grade serous ovarian cancer (LGSOC). The results reveal a significant negative impact of LGSOC on respondents’ m
